子宫内膜癌组织中增殖基因表达情况与患者病理及预后的关系

doi:10.3760/cma.j.cn441417-20240724-06015

国际医药卫生导报 ›› 2025, Vol. 31 ›› Issue (6): 954-959.DOI: 10.3760/cma.j.cn441417-20240724-06015

子宫内膜癌组织中增殖基因表达情况与患者病理及预后的关系

郭玉格¹ 刘维帅² 马平丽¹

¹杨凌示范区医院妇产科，咸阳 712100；²杨凌示范区医院病理科，咸阳 712100

收稿日期:2024-07-24 出版日期:2025-03-15 发布日期:2025-03-17
通讯作者: 刘维帅，Email：liuweishuaiyou@163.com
基金资助:
陕西省自然科学基础研究计划（2021JQ-912）

Relationship between proliferative gene expression in endometrial cancer tissue and patient pathology and prognosis

Guo Yuge¹, Liu Weishuai², Ma Pingli¹

¹Department of Gynecology and Obstetrics, Yangling Demonstration Zone Hospital, Xianyang 712100, China; ²Department of Pathology, Yangling Demonstration Zone Hospital, Xianyang 712100, China

Received:2024-07-24 Online:2025-03-15 Published:2025-03-17
Contact: Liu Weishuai, Email: liuweishuaiyou@163.com
Supported by:
Basic Research Plan of Natural Science in Shaanxi (2021JQ-912)

摘要/Abstract

摘要：

目的　探讨子宫内膜癌组织中增殖基因表达情况与患者病理及预后的关系。方法　选取杨凌示范区医院2018年1月至2022年1月收治的124例子宫内膜癌患者的临床资料，所有患者术后均随访2年，将肿瘤复发、转移和死亡的患者设为预后不良组（43例），其他患者为预后良好组（81例）。采用t检验和χ²检验进行统计比较。通过实时荧光定量聚合酶链式反应（PCR）法检测患者子宫内膜癌组织中增殖基因［增殖细胞核抗原（PCNA）、细胞周期素Dl（cyclin D1）、细胞周期蛋白依赖激酶4（CDK4）］mRNA的相对表达量，并比较不同临床病理特征的子宫内膜癌患者癌组织增殖基因表达水平。通过logistic回归分析评估患者预后不良的影响因素，并利用受试者操作特征曲线（ROC）分析增殖基因在子宫内膜癌患者预后评估中的应用价值。结果　肿瘤低分化、临床分期Ⅲ期、淋巴结转移患者癌组织中PCNA、cyclin Dl、CDK4的表达量更高，差异均有统计学意义（均P0.05）。随访结果显示，预后不良组患者占比34.68%（43/124）；预后不良组PCNA、cyclin Dl、CDK4的表达量分别为3.05±0.56、2.48±0.44、2.14±0.32，预后良好组分别为2.31±0.51、1.79±0.38、1.81±0.24，差异均有统计学意义（均P0.05）。多因素分析表明，肿瘤分化程度、临床分期、淋巴结转移和增殖基因表达量均是影响患者预后的重要因素（均P0.05）。ROC表明，联合检测增殖基因表达量对患者预后预测的曲线下面积为0.970。结论　子宫内膜癌患者癌组织中增殖基因表达情况与预后密切相关。

关键词:

子宫内膜癌, 增殖基因, 临床病理特征, 预后不良

Abstract:

Objective　To explore the relationship between proliferative gene expression in endometrial cancer tissue and patient pathology and prognosis. Methods　The clinical data of 124 patients with endometrial cancer treated at Yangling Demonstration Zone Hospital from January 2018 to January 2022 were collected. All the patients were followed up for 2 years after the surgery. The patients who experienced cancer recurrence, metastasis, or death were classified into a poor prognosis group (43 cases), while the others were classified into a good prognosis group (81 cases). t and χ² tests were used for the statistical comparisons. The relative expression levels of proliferation genes [proliferating cell nuclear antigen (PCNA), cyclin D1, and cyclin-dependent kinase 4 (CDK4)] mRNA in the endometrial cancer tissue were measured by the real-time quantitative polymerase chain reaction (PCR), and the expression levels were compared between the patients with different clinicopathological characteristics. The logistic regression analysis was used to evaluate the factors influencing their poor prognosis. The applicability of proliferation genes in the patients' prognostic assessment was analyzed by the receiver operating characteristic curves (ROC). Results　The patients with poorly differentiated tumors, clinical stage Ⅲ, and lymph node metastasis had higher expression levels of PCNA, cyclinD1, and CDK4 in cancer tissue, with statistical differences (all P0.05). The follow-up results showed that the proportion of the patients with poor prognosis was 34.68% (43/124). The expression levels of PCNA, cyclinD1, and CDK4 in the poor prognosis group were higher than those in the good prognosis group (3.05±0.56 vs. 2.31±0.51, 2.48±0.44 vs. 1.79±0.38, and 2.14±0.32 vs. 1.81±0.24), with statistical differences (all P0.05). The multivariate analysis showed that the degree of tumor differentiation, stage, lymph node metastasis, and proliferation gene expression were all important factors affecting the patients' prognosis (all P0.05). ROC showed that the area under the curve of combined detection of proliferative gene expression was 0.970. Conclusion　Proliferative gene expression in endometrial cancer tissue is correlated with the patients' prognosis.

Key words:

Endometrial cancer, Proliferative genes, Clinical pathological features, Poor prognosis

郭玉格刘维帅马平丽.

子宫内膜癌组织中增殖基因表达情况与患者病理及预后的关系 [J]. 国际医药卫生导报, 2025, 31(6): 954-959.

Guo Yuge, Liu Weishuai, Ma Pingli.

Relationship between proliferative gene expression in endometrial cancer tissue and patient pathology and prognosis [J]. International Medicine and Health Guidance News, 2025, 31(6): 954-959.

参考文献

[1] 张晓露,吴琼,王丽,等. 子宫内膜癌应用腹腔镜根治术的疗效及对术后康复的影响[J]. 吉林医学,2023,44(3):626-629. DOI:10.3969/j.issn.1004-0412.2023.03.015.
[2] 宋晓霞,田金,刘玉玲,等. 长链非编码RNA FAM83H-AS1对子宫内膜癌细胞增殖、侵袭和转移的影响[J]. 国际医药卫生导报,2023,29(14):1930-1935. DOI:10.3760/cma.j.issn.1007-1245.2023.14.002.
[3] Restaino S, Poli A, Arcieri M, et al. Molecular classification of endometrial carcinoma on endometrial biopsy: an early prognostic value to guide personalized treatment[J]. Int J Gynecol Cancer, 2024,34(8):1211-1216. DOI: 10.1136/ijgc-2024-005478.
[4] 朱争艳,王彩霞,梁菲梅,等. 早期高危子宫内膜癌患者术后辅助治疗与预后的关系[J]. 中华肿瘤防治杂志,2023,30(2):99-103. DOI:10.16073/j.cnki.cjcpt.2023.02.06.
[5] Berek JS, Matias-Guiu X, Creutzberg C, et al. FIGO staging of endometrial cancer: 2023[J]. Int J Gynaecol Obstet, 2023,162(2):383-394. DOI: 10.1002/ijgo.14923.
[6] McCluggage WG, Bosse T, Gilks CB, et al. FIGO 2023 endometrial cancer staging: too much, too soon?[J]. Int J Gynecol Cancer, 2024,34(1):138-143. DOI: 10.1136/ijgc-2023-004981.
[7] Soovares P, Pasanen A, Similä-Maarala J, et al. Clinical factors and biomarker profiles associated with patient outcome in endometrioid ovarian carcinoma - Emphasis on tumor grade[J]. Gynecol Oncol, 2022,164(1):187-194. DOI: 10.1016/j.ygyno.2021.10.078.
[8] Hermyt E, Zmarzły N, Grabarek B, et al. Interplay between miRNAs and genes associated with cell proliferation in endometrial cancer[J]. Int J Mol Sci, 2019,20(23):6011. DOI: 10.3390/ijms20236011.
[9] 赵临潇,于东升,刘希,等. miR-381靶向HMGB1抑制子宫内膜癌细胞增殖、侵袭和迁移[J]. 中国实验诊断学,2020,24(6):989-995. DOI:10.3969/j.issn.1007-4287.2020. 06.030.
[10] Zheng C, Wang Y, Bi B, et al. Gallic acid ameliorates endometrial hyperplasia through the inhibition of the PI3K/AKT pathway and the down-regulation of cyclin D1 expression[J]. J Pharmacol Sci, 2024,155(1):1-13. DOI: 10.1016/j.jphs.2024.02.015.
[11] 葛均波, 徐永健. 内科学[M]. 8版. 北京: 人民卫生出版社, 2014: 456-487.
[12] Wright JD, Matsuo K, Huang Y, et al. Prognostic performance of the 2018 International Federation of Gynecology and Obstetrics Cervical Cancer Staging Guidelines[J]. Obstet Gynecol, 2019,134(1):49-57. DOI: 10.1097/AOG.0000000000003311.
[13] Khatib G, Gulec UK, Guzel AB, et al. Prognosis trend of grade 2 endometrioid endometrial carcinoma: toward grade 1 or 3?[J]. Pathol Oncol Res, 2020,26(4):2351-2356. DOI: 10.1007/s12253-020-00836-w.
[14] Skingen VE, Hompland T, Fjeldbo CS, et al. Prostate cancer radiogenomics reveals proliferative gene expression programs associated with distinct MRI-based hypoxia levels[J]. Radiother Oncol, 2023,188:109875. DOI: 10.1016/j.radonc.2023.109875.
[15] 季维雪,孙磊,江玉,等. ADH1B基因甲基化对卵巢癌细胞增殖及凋亡的影响[J]. 安徽医科大学学报,2022,57(8):1274-1278. DOI:10.19405/j.cnki.issn1000-1492.2022.　08.018.
[16] Zambalde ÉP, Pavan ICB, Mancini MCS, et al. Characterization of the interaction between SARS-CoV-2 membrane protein (M) and proliferating cell nuclear antigen (PCNA) as a potential therapeutic target[J]. Front Cell Infect Microbiol, 2022,12:849017. DOI: 10.3389/fcimb.2022.849017.
[17] Liu J, Qian J, Mo Q, et al. LncRNA NR2F2-AS1 silencing induces cell cycle arrest in G0/G1 Phase via downregulating cyclin D1 in colorectal cancer[J]. Cancer Manag Res, 2020,12:1835-1843. DOI: 10.2147/CMAR.S221996.
[18] 李大众,黄敏敏,刘慧玲. 富含半胱氨酸蛋白61对子宫内膜癌细胞增殖及细胞周期的影响及其机制研究[J]. 中国现代医学杂志,2022,32(21):13-17. DOI:10.3969/j.issn.1005- 8982.2022.21.003.
[19] Lashen A, Algethami M, Alqahtani S, et al. The clinicopathological significance of the cyclin D1/E1-Cyclin-Dependent kinase (CDK2/4/6)-retinoblastoma (RB1/pRB1) pathway in epithelial ovarian cancers[J]. Int J Mol Sci, 2024,25(7):4060. DOI: 10.3390/ijms25074060.
[20] 陈茜,刘芳芳,赵颖,等.α-平滑肌肌动蛋白在低分化子宫内膜癌中的预后意义[J].中国妇产科临床杂志,2023,24(06):619-622.DOI:10.13390/j.issn.1672-1861.2023.06.014.
[21] Peng B, Ortega J, Gu L, et al. Phosphorylation of proliferating cell nuclear antigen promotes cancer progression by activating the ATM/Akt/GSK3β/Snail signaling pathway[J]. J Biol Chem, 2019,294(17):7037-7045. DOI: 10.1074/jbc.RA119.007897.
[22] 李雯,李毅,王中卫,等. Genistein通过上调Cyclin D1和CDK4的表达促进卵巢癌OVCAR-5细胞的增殖[J]. 西安交通大学学报(医学版),2021,42(1):59-64. DOI:10.7652/jdyxb202101011.
[23] Khandagale P, Thakur S, Acharya N. Identification of PCNA-interacting protein motifs in human DNA polymerase δ[J]. Biosci Rep, 2020,40(4):BSR20200602. DOI: 10.1042/BSR20200602.
[24] Madru C, Henneke G, Raia P, et al. Structural basis for the increased processivity of D-family DNA polymerases in complex with PCNA[J]. Nat Commun, 2020,11(1):1591. DOI: 10.1038/s41467-020-15392-9.
[25] Huang Y, Wu H, Li X. Novel sequential treatment with palbociclib enhances the effect of cisplatin in RB-proficient triple-negative breast cancer[J]. Cancer Cell Int, 2020,20:501. DOI: 10.1186/s12935-020-01597-x.
[26] Moreno E, Pandit SK, Toussaint MJM, et al. Atypical E2Fs either counteract or cooperate with RB during tumorigenesis depending on tissue context[J]. Cancers (Basel), 2021,13(9):2033. DOI: 10.3390/cancers 13092033.
[27] Wang Z, Shi S, Ren H, et al. Tumor differentiation is the dominant prognostic factor for patients with colorectal neuroendocrine neoplasms with distant metastasis[J]. Int J Endocrinol, 2022,2022:1720624. DOI: 10.1155/2022/1720624.
[28] Berg HF, Ju Z, Myrvold M, et al. Development of prediction models for lymph node metastasis in endometrioid endometrial carcinoma[J]. Br J Cancer, 2020,122(7):1014-1022. DOI: 10.1038/s41416-020-0745-6.
[29] 吴克姣,陈明光,刘继英.82例子宫内膜癌错配修复蛋白表达与临床病理特征的关系[J].广州医药,2023,54(12):44-48.DOI:10.3969/j.issn.1000-8535.2023.12.007.
[30] Song J, Hao L, Zeng X, et al. A novel miRNA Y-56 targeting IGF-1R mediates the proliferation of porcine skeletal muscle satellite cells through AKT and ERK pathways[J]. Front Vet Sci, 2022 ,9:754435. DOI: 10.3389/fvets. 2022.754435.

子宫内膜癌组织中增殖基因表达情况与患者病理及预后的关系

Relationship between proliferative gene expression in endometrial cancer tissue and patient pathology and prognosis

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 5

编辑推荐

Metrics

[1]	张国坤张天佑张景畅李素新. 原发性肝癌患者TACE预后不良的因素分析：基于PSM法 [J]. 国际医药卫生导报, 2024, 30(5): 747-753.
[2]	折文利徐鑫利李彦婷李新. 超声及临床病理特征对甲状腺乳头状癌Delphian淋巴结转移的诊断价值 [J]. 国际医药卫生导报, 2024, 30(17): 2951-2956.
[3]	张丽柯徐全晓李媛媛杨卫. 胃癌组织中NF-κB、PD-1、PD-L1的表达及其临床意义 [J]. 国际医药卫生导报, 2024, 30(15): 2519-2523.
[4]	丁佰娟张立伟杨慧崔秀娟李南. IGSF9在上皮性卵巢癌中的表达及对卵巢癌细胞转移能力的影响 [J]. 国际医药卫生导报, 2023, 29(16): 2268-2272.
[5]	杨汉顾玉兰. 神经纤毛蛋白-1在胃癌组织中的表达与临床病理特征及预后相关性的meta分析[J]. 国际医药卫生导报, 2022, 28(22): 3246-3251.